Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms
- 442 Downloads
To compare Pueraria mirifica 25 and 50 mg dosages to relieve menopausal symptoms.
A double-blind study was conducted on 52 hysterectomized women with menopausal symptoms who had an indication for hormone therapy. The women were randomly allocated into two groups receiving either Pueraria mirifica 25 mg tablet (Arm A; n = 26) or Pueraria mirifica 50 mg (Arm B; n = 26) for 6 months. Menopausal symptoms, physical examination findings, and laboratory data were recorded at baseline. Symptoms were reevaluated at 3 and 6 months, while physical and laboratory examinations were evaluated at 1 month and at the end of treatment. A modified Green climacteric scale was used to evaluate menopausal symptoms; a score of ≥15 indicated estrogen deficiency.
All women completed the study. Mean baseline climacteric scores of women who received 25 and 50 mg were: 24.19 ± 9.11 versus 23.19 ± 7.89, respectively (p = 0.674). After 3 and 6 months of treatment, scores were 17.92 ± 10.40 versus 15.35 ± 8.44 (p = 0.332) and 14.08 ± 10.30 versus 12.46 ± 6.38 (p = 0.500), respectively. No significant side effects were observed with Pueraria mirifica 25 or 50 mg.
Both dosages of Pueraria mirifica were similarly effective and safe in the treatment of menopausal symptoms.
KeywordsPueraria mirifica Modified Green climacteric scale Menopausal symptoms
This study was supported by a grant from The Thai Traditional Medical Knowledge Fund, The Institute of Thai Traditional Medicine, Ministry of Public Health of Thailand. The sponsors were not involved in any aspect of this research. The authors would like to thank Dr. Budsaba Wiriyasirivaj and Dr. Sumonmal Manusirivithaya for their assistance in statistical analysis and Dr. Siriwan Tangjitgamol for the manuscript preparation.
Conflict of interest
The authors declare that we have no conflict of interest.
- 2.North American Menopause Society (2007) Menopause practice: a clinician’s guide, 3rd ed. Cleveland, OH, North American Menopause Society, pp 9–18Google Scholar
- 5.Dewicks PM (1995) Isoflavonoids. In: Harborne JB (ed) The flavonoid. Dhapman & Hall, London, pp 117–238Google Scholar
- 7.Sukavaj T (1949) Herbal medicine. Thai J Med Sci 3:104–110Google Scholar
- 11.Chandeying V, Lamlertkittikul S (2007) Challenges in the conduct of Thai herbal scientific study: effectiveness and safety of phytoestrogen, Pueraria mirifica (Kwao Kuer Kao), phase I, in the alleviation of climacteric symptoms in perimenopausal women. J Med Assoc Thai 90:1274–1280PubMedGoogle Scholar
- 12.Chandeying V, Sangthawan M (2007) Effectiveness comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study. J Med Assoc Thai 90:1720–1726PubMedGoogle Scholar
- 13.Speroff L, Fritz MA (2005) Clinical gynecologic endocrinology and infertility, 7th edn. Williams & Wilkins, Philadelphia, Lippincott, pp 689–777Google Scholar
- 14.Smitasiri Y, Junyatum U, Songjitsawad A, Sripromma P, Trisrisilp S, Anuntalabhochai S (1986) Postcoital antifertility effects of Pueraria mirifica in rats. J Sci Fac Chiang Mai Univ 13:19–28Google Scholar
- 15.MacLennan A (1996) Symptoms and signs of the climacteric. In: Wren BG, Nachtigall LE (eds) Clinical management of the menopause. McGraw-Hill, Roseville, pp 7–15Google Scholar
- 17.Ettinger B (2005) Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 118 (Suppl 12B):74–8Google Scholar
- 20.Mundy GR (2007) Osteoporosis and inflammation. Nutr Rev 65(12 Pt 2): S147–S151Google Scholar
- 21.Wang KC, Lin YF, Qin CH, Chen TL, Chen CH (2010) Bisphenol-A interferes with estradiol-mediated protection in osteoarthritic chondrocytes. Toxicol Lett 5; 198(2):127–133Google Scholar
- 24.Dijsselbloem N, Vanden BW, De NA, Haegeman G (2004) Soy isoflavones phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 15; 68(6):1171–1185Google Scholar
- 26.Sarrel PM (1990) Sexuality and menopause. Obstet Gynecol 75(4Suppl):26S–30S; discussion 31S–35SGoogle Scholar
- 27.Kicovic PM, Cortes-Prieto J, Milojevic S, Haspels AA, Aljinovic A (1980) The treatment of postmenopause vaginal atrophy with Ovestin vaginal cream or suppositories: clinical endocrinological and safety aspects. Maturitas 14:23–31Google Scholar
- 30.Kongnyuy EJ, Norman RJ, Flight IHK, Rees MC (2005) Oestrogen and progestogen hormone replacement therapy for perimenopausal and post-menopausal women: weight and body fat distribution. Cochrane Database of Systematic Reviews, Issue 3. Art. no.: CD001018. doi: 10.1002/14651858
- 31.Sanchanta P, Saenphet K, Saenphet S, Aritajat S, Wongsawad C (2005) Toxicological study of aqueous and ethanolic extracts from Pueraria mirifica Airy Shaw and Suvatabandhu on male rats. In: Brovelli E, Chansakaow S, Farias D et al (eds) III WOCMAP congress on medicinal and aromatic plants—volume 5: quality, effectiveness, safety, processing and trade in medicinal and aromatic plants. International Society for Horticultural Science, Leuven, BelgiumGoogle Scholar
- 32.Egeland GM, Kuller LH, Matthews KA, Kelsey SF, Cauley J, Guzick D (1990) Hormone replacement therapy and lipoprotein changes during early menopause. Obstet Gynecol Nov 76(5 pt 1):776–782Google Scholar